Form 4: Director Sells SONN Shares Post-Merger with Hyperliquid

Nailesh Bhatt, a director at Sonnet BioTherapeutics Holdings, Inc., reported the disposition of 10,547 common shares following the company's merger into Hyperliquid Strategies Inc.

Summary

• Nailesh Bhatt, a director of Sonnet BioTherapeutics Holdings, Inc. (SONN), reported a change in beneficial ownership.
• On December 2, 2025, 10,547 shares of SONN Common Stock were disposed of.
• This transaction occurred as a result of a Business Combination Agreement (BCA) dated July 11, 2025.
• Under the BCA, Sonnet BioTherapeutics Holdings, Inc. merged into Hyperliquid Strategies Inc. (HSI), becoming a direct wholly-owned subsidiary of HSI.
• The disposed shares included 10,000 restricted stock units granted on July 11, 2025, which vested at the merger's effective time, and 547 previously vested restricted stock units.
• Each restricted stock unit was exchanged for one-fifth of a share of HSI Common Stock and one Contingent Value Right (CVR).
• All reported amounts reflect prior reverse stock splits: 1:22 effective August 31, 2023, and 1:8 effective September 30, 2024.
• Following this transaction, Nailesh Bhatt beneficially owns 0 shares of Sonnet BioTherapeutics Holdings, Inc.

Sentiment

Score: 6

Explanation: The filing reports a director's share disposition following a merger, which is a neutral event in itself. The merger's completion is a positive for the strategic transition, but the prior reverse stock splits suggest underlying challenges for the acquired entity. The conversion to HSI stock and CVRs offers potential future value.

Positives

• The merger with Hyperliquid Strategies Inc. (HSI) has been completed, indicating a strategic transition for Sonnet BioTherapeutics.
• The reporting person's restricted stock units vested as a result of the merger, converting into HSI Common Stock and CVRs.

Negatives

• Sonnet BioTherapeutics Holdings, Inc. is no longer an independent publicly traded entity, having become a wholly-owned subsidiary of HSI.
• The reporting person no longer holds direct beneficial ownership in Sonnet BioTherapeutics Holdings, Inc. common stock.

Future Outlook

The filing primarily reports a past transaction (the merger and subsequent share disposition) and does not contain explicit forward-looking statements or guidance regarding the future performance of HSI or the former Sonnet operations. The conversion to HSI stock and CVRs implies future value tied to HSI's performance and the CVR terms.

Industry Context

This filing indicates a consolidation event within the biotechnology or pharmaceutical sector, where Sonnet BioTherapeutics, a company that has undergone significant reverse stock splits, has been acquired by Hyperliquid Strategies Inc. Such mergers often occur for strategic reasons, including market expansion, technology acquisition, or to address financial challenges. The issuance of CVRs suggests that part of the deal value is contingent on future performance milestones, common in biotech acquisitions.

Comparison to Industry Standards

• The merger and acquisition (M&A) activity is a common strategy in the biotechnology and pharmaceutical industries for companies to gain market share, access new technologies, or streamline operations.
• The use of Contingent Value Rights (CVRs) in the merger consideration is a standard practice in biotech acquisitions, particularly when there is uncertainty regarding the future value of pipeline assets or specific milestones. For example, similar structures have been seen in deals like Sanofi's acquisition of Principia Biopharma or Bristol-Myers Squibb's acquisition of Celgene, where CVRs were tied to regulatory approvals or sales milestones.
• The prior reverse stock splits (1:22 and 1:8) for Sonnet BioTherapeutics Holdings, Inc. suggest the company faced challenges maintaining its stock price, a common precursor to acquisition or delisting for smaller biotech firms.

Stakeholder Impact

• Shareholders (former SONN): Their shares were exchanged for HSI Common Stock and CVRs, meaning their investment is now tied to HSI's performance and the CVR terms.
• Employees (former SONN): The merger likely impacts employees, though not detailed here. The vesting of RSUs for the director suggests similar treatment for other RSU holders.
• Management (former SONN): The director's transaction reflects the completion of the merger, indicating a shift in corporate structure and potentially management roles within the new HSI subsidiary.

Next Steps

• Monitoring the performance of Hyperliquid Strategies Inc. (HSI) Common Stock received by former Sonnet shareholders.
• Tracking the terms and potential payouts of the Contingent Value Rights (CVRs) issued as part of the merger consideration.

Key Dates

Recommendation

The filing details the mandatory disposition of Sonnet BioTherapeutics Holdings, Inc. shares by a director as a direct consequence of the company's merger into Hyperliquid Strategies Inc. Former SONN shareholders now hold HSI Common Stock and Contingent Value Rights (CVRs). A seasoned investor would likely hold these new securities to benefit from the potential upside of HSI's future performance and the specific terms of the CVRs, rather than immediately selling the newly acquired HSI shares, as the merger itself represents a strategic move. The prior reverse stock splits indicate past challenges for SONN, but the merger offers a new investment vehicle.

Keywords

Sonnet BioTherapeutics Holdings Inc., SONN, Hyperliquid Strategies Inc., HSI, Merger, Business Combination Agreement, Form 4, Beneficial Ownership, Restricted Stock Units, CVR, Director Transaction, Nailesh Bhatt